Drugs /

nadofaragene firadenovec

Back to Drugs List

Overview

NCI Definition [1]:
A replication-deficient recombinant adenovirus encoding human interferon alpha-2b with potential antineoplastic activity. Upon intravesical administration, recombinant adenovirus-interferon SCH 721015 infects nearby tumor cells and expresses INF alpha-2b intracellularly which activates the transcription and translation of genes whose products mediate antiviral, antiproliferative, antitumor, and immune-modulating effects.

Clinical Trials

View Clinical Trials for nadofaragene firadenovec

Nadofaragene firadenovec has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating nadofaragene firadenovec, 1 is phase 3 (1 open).

Pleural biphasic mesothelioma and pleural epithelioid mesothelioma are the most common diseases being investigated in nadofaragene firadenovec clinical trials [2].

Drug Details

Synonyms [2]:
instiladrin, rad-ifn, rad-ifn sch 721015, sch 721015, recombinant adenovirus-interferon sch 721015, rad-ifn-2b
NCIT ID [1]:
C71011

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.